Effect of antipsychotic use by patients with schizophrenia on deceleration capacity and its relation to the corrected QT interval

Schizophrenia patients treated with antipsychotics are at higher risk of sudden cardiac death. Decreased deceleration capacity (DC) of the heart rate is an accurate predictor of cardiac mortality. We evaluated the risk of sudden cardiac death due to antipsychotic use by assessing DC and examining th...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:General hospital psychiatry 2023-03, Vol.81, p.15-21
Hauptverfasser: Okayasu, Hiroaki, Shinozaki, Takahiro, Takano, Yumiko, Sugawara, Norio, Fujii, Kumiko, Yasui-Furukori, Norio, Ozeki, Yuji, Shimoda, Kazutaka
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 21
container_issue
container_start_page 15
container_title General hospital psychiatry
container_volume 81
creator Okayasu, Hiroaki
Shinozaki, Takahiro
Takano, Yumiko
Sugawara, Norio
Fujii, Kumiko
Yasui-Furukori, Norio
Ozeki, Yuji
Shimoda, Kazutaka
description Schizophrenia patients treated with antipsychotics are at higher risk of sudden cardiac death. Decreased deceleration capacity (DC) of the heart rate is an accurate predictor of cardiac mortality. We evaluated the risk of sudden cardiac death due to antipsychotic use by assessing DC and examining the association between DC and the corrected QT interval (QTc) in schizophrenia patients. We measured the DC and QTc of 138 schizophrenia patients. We then compared the DC of 86 age- and sex-matched healthy controls with that of 86 schizophrenia patients. We investigated the correlation of DC of approximately 138 schizophrenia patients with prescribed doses of antipsychotics using linear regression analysis. We compared the DC of schizophrenia patients with and without prolonged QT intervals. We found DC significantly differed between schizophrenia patients on antipsychotic medication and healthy controls. Additionally, DC was negatively correlated with antipsychotic use, especially chlorpromazine, zotepine, olanzapine and clozapine, in a dose-dependent manner. There was no significant association between DC and the QTc. Assessing DC could facilitate monitoring and identification of increased risk of cardiac mortality in patients with schizophrenia that take antipsychotics. Assessing both DC and the QTc may enhance the accuracy of predicting sudden cardiac death. •The association of DC with antipsychotic use was examined in 138 persons with schizophrenia.•DC was significantly lower in schizophrenia using medication than in normal controls.•Antipsychotic use had a negative dose-dependent relationship with DC.•Using of chlorpromazine, zotepine, olanzapine, and clozapine was correlated with DC.•No association was observed between DC and the QTc.
doi_str_mv 10.1016/j.genhosppsych.2023.01.005
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2771334753</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0163834323000051</els_id><sourcerecordid>2771334753</sourcerecordid><originalsourceid>FETCH-LOGICAL-c380t-9d6ae56b1ffd9acb08730b7feb195e802349e240c1fe7f06be86a0da1085b0823</originalsourceid><addsrcrecordid>eNqNkUtLJDEUhYM4aPv4CxJcuamapFKvdie-QRgGdB1SyY2VprpSJmml3c0_n9u2yixnFUK-c07uuYSccpZzxuufi_wZxt7HaYpr3ecFK0TOeM5YtUNmvG1E1jS83CUzhEXWilLsk4MYFwyJohJ7ZF_UDa_rqpyRP9fWgk7UW6rG5D4cfXKariLQbk0nlRyMKdI3l3oade_e_dQHGJ2ifqQGNAwQEMKLVpPSLq3RyVCHmgDD9iV5mnqg2oeAYWDo70fqxgThVQ1H5IdVQ4Tjz_OQPN1cP17eZQ-_bu8vLx4yLVqWsrmpFVR1x601c6U7hnOyrrHQ8XkFLXZQzqEomeYWGsvqDtpaMaM4ayuEC3FIzra-U_AvK4hJLl3E3w9qBL-KssDShCibSiB6vkV18DEGsHIKbqnCWnImNyuQC_nvCuRmBZJxiQWj-OQzZ9UtwXxLvzpH4GoLAE776iDIqLFjDcZt2pHGu__J-Qtf1KIm</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2771334753</pqid></control><display><type>article</type><title>Effect of antipsychotic use by patients with schizophrenia on deceleration capacity and its relation to the corrected QT interval</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Okayasu, Hiroaki ; Shinozaki, Takahiro ; Takano, Yumiko ; Sugawara, Norio ; Fujii, Kumiko ; Yasui-Furukori, Norio ; Ozeki, Yuji ; Shimoda, Kazutaka</creator><creatorcontrib>Okayasu, Hiroaki ; Shinozaki, Takahiro ; Takano, Yumiko ; Sugawara, Norio ; Fujii, Kumiko ; Yasui-Furukori, Norio ; Ozeki, Yuji ; Shimoda, Kazutaka</creatorcontrib><description>Schizophrenia patients treated with antipsychotics are at higher risk of sudden cardiac death. Decreased deceleration capacity (DC) of the heart rate is an accurate predictor of cardiac mortality. We evaluated the risk of sudden cardiac death due to antipsychotic use by assessing DC and examining the association between DC and the corrected QT interval (QTc) in schizophrenia patients. We measured the DC and QTc of 138 schizophrenia patients. We then compared the DC of 86 age- and sex-matched healthy controls with that of 86 schizophrenia patients. We investigated the correlation of DC of approximately 138 schizophrenia patients with prescribed doses of antipsychotics using linear regression analysis. We compared the DC of schizophrenia patients with and without prolonged QT intervals. We found DC significantly differed between schizophrenia patients on antipsychotic medication and healthy controls. Additionally, DC was negatively correlated with antipsychotic use, especially chlorpromazine, zotepine, olanzapine and clozapine, in a dose-dependent manner. There was no significant association between DC and the QTc. Assessing DC could facilitate monitoring and identification of increased risk of cardiac mortality in patients with schizophrenia that take antipsychotics. Assessing both DC and the QTc may enhance the accuracy of predicting sudden cardiac death. •The association of DC with antipsychotic use was examined in 138 persons with schizophrenia.•DC was significantly lower in schizophrenia using medication than in normal controls.•Antipsychotic use had a negative dose-dependent relationship with DC.•Using of chlorpromazine, zotepine, olanzapine, and clozapine was correlated with DC.•No association was observed between DC and the QTc.</description><identifier>ISSN: 0163-8343</identifier><identifier>EISSN: 1873-7714</identifier><identifier>DOI: 10.1016/j.genhosppsych.2023.01.005</identifier><identifier>PMID: 36716654</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Antipsychotic Agents - adverse effects ; Antipsychotics ; Death, Sudden, Cardiac - etiology ; Deceleration ; Deceleration capacity ; Heart rate variability ; Humans ; Long QT Syndrome - chemically induced ; Long QT Syndrome - complications ; QT interval ; Schizophrenia ; Schizophrenia - complications ; Schizophrenia - drug therapy ; Sudden cardiac death</subject><ispartof>General hospital psychiatry, 2023-03, Vol.81, p.15-21</ispartof><rights>2023 Elsevier Inc.</rights><rights>Copyright © 2023 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c380t-9d6ae56b1ffd9acb08730b7feb195e802349e240c1fe7f06be86a0da1085b0823</citedby><cites>FETCH-LOGICAL-c380t-9d6ae56b1ffd9acb08730b7feb195e802349e240c1fe7f06be86a0da1085b0823</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0163834323000051$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36716654$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Okayasu, Hiroaki</creatorcontrib><creatorcontrib>Shinozaki, Takahiro</creatorcontrib><creatorcontrib>Takano, Yumiko</creatorcontrib><creatorcontrib>Sugawara, Norio</creatorcontrib><creatorcontrib>Fujii, Kumiko</creatorcontrib><creatorcontrib>Yasui-Furukori, Norio</creatorcontrib><creatorcontrib>Ozeki, Yuji</creatorcontrib><creatorcontrib>Shimoda, Kazutaka</creatorcontrib><title>Effect of antipsychotic use by patients with schizophrenia on deceleration capacity and its relation to the corrected QT interval</title><title>General hospital psychiatry</title><addtitle>Gen Hosp Psychiatry</addtitle><description>Schizophrenia patients treated with antipsychotics are at higher risk of sudden cardiac death. Decreased deceleration capacity (DC) of the heart rate is an accurate predictor of cardiac mortality. We evaluated the risk of sudden cardiac death due to antipsychotic use by assessing DC and examining the association between DC and the corrected QT interval (QTc) in schizophrenia patients. We measured the DC and QTc of 138 schizophrenia patients. We then compared the DC of 86 age- and sex-matched healthy controls with that of 86 schizophrenia patients. We investigated the correlation of DC of approximately 138 schizophrenia patients with prescribed doses of antipsychotics using linear regression analysis. We compared the DC of schizophrenia patients with and without prolonged QT intervals. We found DC significantly differed between schizophrenia patients on antipsychotic medication and healthy controls. Additionally, DC was negatively correlated with antipsychotic use, especially chlorpromazine, zotepine, olanzapine and clozapine, in a dose-dependent manner. There was no significant association between DC and the QTc. Assessing DC could facilitate monitoring and identification of increased risk of cardiac mortality in patients with schizophrenia that take antipsychotics. Assessing both DC and the QTc may enhance the accuracy of predicting sudden cardiac death. •The association of DC with antipsychotic use was examined in 138 persons with schizophrenia.•DC was significantly lower in schizophrenia using medication than in normal controls.•Antipsychotic use had a negative dose-dependent relationship with DC.•Using of chlorpromazine, zotepine, olanzapine, and clozapine was correlated with DC.•No association was observed between DC and the QTc.</description><subject>Antipsychotic Agents - adverse effects</subject><subject>Antipsychotics</subject><subject>Death, Sudden, Cardiac - etiology</subject><subject>Deceleration</subject><subject>Deceleration capacity</subject><subject>Heart rate variability</subject><subject>Humans</subject><subject>Long QT Syndrome - chemically induced</subject><subject>Long QT Syndrome - complications</subject><subject>QT interval</subject><subject>Schizophrenia</subject><subject>Schizophrenia - complications</subject><subject>Schizophrenia - drug therapy</subject><subject>Sudden cardiac death</subject><issn>0163-8343</issn><issn>1873-7714</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkUtLJDEUhYM4aPv4CxJcuamapFKvdie-QRgGdB1SyY2VprpSJmml3c0_n9u2yixnFUK-c07uuYSccpZzxuufi_wZxt7HaYpr3ecFK0TOeM5YtUNmvG1E1jS83CUzhEXWilLsk4MYFwyJohJ7ZF_UDa_rqpyRP9fWgk7UW6rG5D4cfXKariLQbk0nlRyMKdI3l3oade_e_dQHGJ2ifqQGNAwQEMKLVpPSLq3RyVCHmgDD9iV5mnqg2oeAYWDo70fqxgThVQ1H5IdVQ4Tjz_OQPN1cP17eZQ-_bu8vLx4yLVqWsrmpFVR1x601c6U7hnOyrrHQ8XkFLXZQzqEomeYWGsvqDtpaMaM4ayuEC3FIzra-U_AvK4hJLl3E3w9qBL-KssDShCibSiB6vkV18DEGsHIKbqnCWnImNyuQC_nvCuRmBZJxiQWj-OQzZ9UtwXxLvzpH4GoLAE776iDIqLFjDcZt2pHGu__J-Qtf1KIm</recordid><startdate>202303</startdate><enddate>202303</enddate><creator>Okayasu, Hiroaki</creator><creator>Shinozaki, Takahiro</creator><creator>Takano, Yumiko</creator><creator>Sugawara, Norio</creator><creator>Fujii, Kumiko</creator><creator>Yasui-Furukori, Norio</creator><creator>Ozeki, Yuji</creator><creator>Shimoda, Kazutaka</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202303</creationdate><title>Effect of antipsychotic use by patients with schizophrenia on deceleration capacity and its relation to the corrected QT interval</title><author>Okayasu, Hiroaki ; Shinozaki, Takahiro ; Takano, Yumiko ; Sugawara, Norio ; Fujii, Kumiko ; Yasui-Furukori, Norio ; Ozeki, Yuji ; Shimoda, Kazutaka</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c380t-9d6ae56b1ffd9acb08730b7feb195e802349e240c1fe7f06be86a0da1085b0823</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Antipsychotic Agents - adverse effects</topic><topic>Antipsychotics</topic><topic>Death, Sudden, Cardiac - etiology</topic><topic>Deceleration</topic><topic>Deceleration capacity</topic><topic>Heart rate variability</topic><topic>Humans</topic><topic>Long QT Syndrome - chemically induced</topic><topic>Long QT Syndrome - complications</topic><topic>QT interval</topic><topic>Schizophrenia</topic><topic>Schizophrenia - complications</topic><topic>Schizophrenia - drug therapy</topic><topic>Sudden cardiac death</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Okayasu, Hiroaki</creatorcontrib><creatorcontrib>Shinozaki, Takahiro</creatorcontrib><creatorcontrib>Takano, Yumiko</creatorcontrib><creatorcontrib>Sugawara, Norio</creatorcontrib><creatorcontrib>Fujii, Kumiko</creatorcontrib><creatorcontrib>Yasui-Furukori, Norio</creatorcontrib><creatorcontrib>Ozeki, Yuji</creatorcontrib><creatorcontrib>Shimoda, Kazutaka</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>General hospital psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Okayasu, Hiroaki</au><au>Shinozaki, Takahiro</au><au>Takano, Yumiko</au><au>Sugawara, Norio</au><au>Fujii, Kumiko</au><au>Yasui-Furukori, Norio</au><au>Ozeki, Yuji</au><au>Shimoda, Kazutaka</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of antipsychotic use by patients with schizophrenia on deceleration capacity and its relation to the corrected QT interval</atitle><jtitle>General hospital psychiatry</jtitle><addtitle>Gen Hosp Psychiatry</addtitle><date>2023-03</date><risdate>2023</risdate><volume>81</volume><spage>15</spage><epage>21</epage><pages>15-21</pages><issn>0163-8343</issn><eissn>1873-7714</eissn><abstract>Schizophrenia patients treated with antipsychotics are at higher risk of sudden cardiac death. Decreased deceleration capacity (DC) of the heart rate is an accurate predictor of cardiac mortality. We evaluated the risk of sudden cardiac death due to antipsychotic use by assessing DC and examining the association between DC and the corrected QT interval (QTc) in schizophrenia patients. We measured the DC and QTc of 138 schizophrenia patients. We then compared the DC of 86 age- and sex-matched healthy controls with that of 86 schizophrenia patients. We investigated the correlation of DC of approximately 138 schizophrenia patients with prescribed doses of antipsychotics using linear regression analysis. We compared the DC of schizophrenia patients with and without prolonged QT intervals. We found DC significantly differed between schizophrenia patients on antipsychotic medication and healthy controls. Additionally, DC was negatively correlated with antipsychotic use, especially chlorpromazine, zotepine, olanzapine and clozapine, in a dose-dependent manner. There was no significant association between DC and the QTc. Assessing DC could facilitate monitoring and identification of increased risk of cardiac mortality in patients with schizophrenia that take antipsychotics. Assessing both DC and the QTc may enhance the accuracy of predicting sudden cardiac death. •The association of DC with antipsychotic use was examined in 138 persons with schizophrenia.•DC was significantly lower in schizophrenia using medication than in normal controls.•Antipsychotic use had a negative dose-dependent relationship with DC.•Using of chlorpromazine, zotepine, olanzapine, and clozapine was correlated with DC.•No association was observed between DC and the QTc.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>36716654</pmid><doi>10.1016/j.genhosppsych.2023.01.005</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0163-8343
ispartof General hospital psychiatry, 2023-03, Vol.81, p.15-21
issn 0163-8343
1873-7714
language eng
recordid cdi_proquest_miscellaneous_2771334753
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects Antipsychotic Agents - adverse effects
Antipsychotics
Death, Sudden, Cardiac - etiology
Deceleration
Deceleration capacity
Heart rate variability
Humans
Long QT Syndrome - chemically induced
Long QT Syndrome - complications
QT interval
Schizophrenia
Schizophrenia - complications
Schizophrenia - drug therapy
Sudden cardiac death
title Effect of antipsychotic use by patients with schizophrenia on deceleration capacity and its relation to the corrected QT interval
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T20%3A07%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20antipsychotic%20use%20by%20patients%20with%20schizophrenia%20on%20deceleration%20capacity%20and%20its%20relation%20to%20the%20corrected%20QT%20interval&rft.jtitle=General%20hospital%20psychiatry&rft.au=Okayasu,%20Hiroaki&rft.date=2023-03&rft.volume=81&rft.spage=15&rft.epage=21&rft.pages=15-21&rft.issn=0163-8343&rft.eissn=1873-7714&rft_id=info:doi/10.1016/j.genhosppsych.2023.01.005&rft_dat=%3Cproquest_cross%3E2771334753%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2771334753&rft_id=info:pmid/36716654&rft_els_id=S0163834323000051&rfr_iscdi=true